Network meta-analysis of novel diagnostic biomarkers for rheumatoid arthritis: comparative performance of anti-CarP, anti-MCV, and emerging markers - Takeaways - MDSpire

Network meta-analysis of novel diagnostic biomarkers for rheumatoid arthritis: comparative performance of anti-CarP, anti-MCV, and emerging markers

  • By

  • Guanghui Li

  • Limin Tan

  • Jiayan Liu

  • Manxiang Wang

  • June 16, 2026

  • 0 min

Share

  • 1

    This network meta-analysis evaluated the diagnostic performance of seven novel biomarkers for rheumatoid arthritis.

  • 2

    Anti-carbamylated protein (Anti-CarP) antibody exhibited the highest diagnostic efficacy among the biomarkers assessed.

  • 3

    Anti-mutated citrullinated vimentin (Anti-MCV) ranked second in diagnostic performance following Anti-CarP.

  • 4

    The 14-3-3 η protein demonstrated limited diagnostic utility, challenging previous assumptions about its effectiveness.

  • 5

    Standardized thresholds and direct comparisons are necessary for validating these biomarkers in early-stage rheumatoid arthritis.

Original Source(s)

Network meta-analysis of novel diagnostic biomarkers for rheumatoid arthritis: comparative performance of anti-CarP, anti-MCV, and emerging markers

  • by Guanghui Li, Limin Tan, Jiayan Liu, Manxiang Wang

  • June 16, 2026

Related Content

Trial Exclusions May Skew RA Drug Comparisons

Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.

CORO1A links inflammatory chondrocyte subpopulations to immune microenvironment alterations in osteoarthritis: an integrative multi-omics and single-cell study

From uric acid to tophi: multistage molecular and cellular mechanisms of tophi formation